Innovation and excellence in science and health

ABC Data Meeting Delegates

Meeting Overview with directions to venue – click here

Programme – click here

Discussion guidelines – click here

Resources and information – click here


 

Delegate biographies (listed in alphabetical order)

 


Tim AndrewsDr Tim Andrews
Managing Partner, Cambridge
Marks & Clerk

Tim is a patent attorney specialising in chemistry, especially pharmaceutical, organic and polymer chemistry and petrochemicals. He is Managing Partner of the Cambridge Office and acts for a wide variety of clients including a number of Cambridge companies such as a major pharmaceutical company active in the field of formulations for pain relief and a number of academic institutions including Cambridge University, as well as global life science companies including a leader in the development of novel cancer therapeutics. His practice involves the drafting, filing and prosecution of patent applications and Supplementary Protection Certificates worldwide, EPO opposition and appeal work, and the preparation of infringement and validity opinions, due diligence reports and IP audits. His experience with big data is in considering its potential as a source for innovation through the open innovation model, and the implications for IP generated.

 


 

Lawrence AshelfordLawrence Ashelford
Director of Strategy, Policy and Planning,
Cambridge University Hospitals NHS Foundation Trust

 

 

 

Lawrence joined Cambridge University Hospitals (Addenbrookes) in September 2004 from Local Government where he worked in social care and on corporate development. He has been involved in the UK social care and healthcare sectors for over 25 years and has extensive experience implementing new government policy at strategic and operational levels, service development, business planning and public sector investment. Since joining Addenbrookes, Lawrence has provided a lead for trust-wide strategy, policy analysis and development, trust-wide business planning, clinical strategy development and service development. He has also specialised in individual and group work to implement change across all clinical service areas. Prior to joining the trust, Lawrence worked in the UK’s first integrated Primary Care Trust and Social Services Department where his roles included responsibility for service planning and development, finance, HR, ICT and facilities management; and running a large operational service. He also spent a year establishing a Council-wide customer first programme which involved streamlining and integrating access to and delivery of all council services, E government and marketing.


 

Emmanuelle AstoulDr Emmanuelle Astoul
Business Development Manager, Translation Office
Wellcome Trust Sanger Institute

 

 

 

 


 

Sarah BarberDr Sarah Barber
Head of the Information Practice in Biometrics and Information Sciences
AstraZeneca

Sarah has a first degree in Natural Sciences and a PhD in Physical Organic Chemistry from the University of Cambridge. Her career at AstraZeneca began in the laboratories in process development and moved into manufacturing and operations before a transition to R&D as a project manager and then leader of Global Product Development teams in Oncology. Today she leads Information Practice – a group with a passion for optimizing the use of information in our drug development decision making. The work of the group includes:-

  • Responsible sharing of patient level data internally and externally (data transparency)
  • Seeking out accurate benchmarking data to inform estimates of the likelihood of our medicines in development reaching their intended patients.
  • Participation in initiatives aimed at enhancing our use of data and information to bring improvements in our understanding of disease and in bringing new medicines to patients. Examples include the European Innovative Medicines Initiative project EHR4CR (Electronic Health Records for Clinical Research) and the CEO Life Sciences Consortium Project Datasphere (an open access database of control arms from oncology trials).

 


 

Richard BartlettRichard Bartlett
Head of Clinical School Computing Service
University of Cambridge

I have over 20 years’ experience in IT, 10 of them in IT Management roles, and I’m currently working as Head of the Clinical School Computing Service, one of the largest IT Service Providers in the University of Cambridge. I am responsible for the IT Service delivery for the departments, institutes and units (approximately 25) within the School of Clinical Medicine plus a smaller number of departments in the School of Biological Sciences. I manage a department of 23 staff, and an annual budget in excess of £1.2 million. The Clinical School Computing Service provides IT services including the provision of a campus wide data and telephone network (4000 direct attached devices), data storage (300TB) using SAN equipment and in excess of 120 servers (virtual and physical). We are currently reviewing our data storage to meet the growing demand for large scale storage, including long term archiving, and satisfying the requirements of open access.

 


 

Gordon BaxterDr Gordon Baxter
Chief Executive
Instem

 

 

 


 

David-BentleyDr David Bentley
Vice President & Chief Scientist
Illumina Inc.

David graduated with an M.A. in Natural Sciences from Cambridge and a D.Phil from Oxford. During his career he has been a Senior Lecturer at London University; and later the Head of Human Genetics and a founder member of the Board of Management at the Sanger Centre. David has played a leading role in the Human Genome Project and related international consortia to characterise human sequence variation, including The SNP Consortium and the HapMap Project. His long-term interest is the study of human sequence variation and its impact on human health and disease. His current research is focussed on fast, accurate sequencing of human genomes for adoption and benefit in healthcare.

 


 

BlankMs Jane Berezynskyj
Associate Director for IT and Estates Change Projects
Cambridgeshire and Peterborough NHS Foundation Trust

I have over 20 years’ experience in IT project and programme management and have successfully delivered a wide variety of IT and business transformation projects primarily in private sector organisations and latterly within the public sector for the NHS.  As a languages graduate, I am able to talk both technical and business and am an effective intermediary between the two worlds.  Having worked in service organisations, working collaboratively across organisational boundaries was a necessity as was understanding and brokering interests between supplier and customer organisations.  And this where my current role is now heading as I’m responsible for delivering the IT and Estates capital plan. Having delivered the Electronic Patient Record as the foundation stone for clinical data capture in Cambridgeshire and Peterborough NHS FT, I’m helping the Trust and the wider health economy to progress the further development and extension of the clinical record and leveraging the information sharing potential that now exists.

 

 


 

Sheila Bird

Professor Sheila Bird

Programme Leader

MRC Biostatistics Unit

Sheila Bird OBE FRSE is visiting professor at the University of Strathclyde’s Department of Mathematics and Statistics, and Programme Leader at the MRC Biostatistics Unit, Institute of Public Health, Cambridge. She has been a Medicines Commissioner, was the first statistician on NICE’s Appraisal Committee, and has served on four Royal Statistical Society Working Parties as well as on various Medical Research Council, UK government and EU Working Parties and Groups. Bird have oral evidence to the Science and Technology Select Committee Inquiries into Scientific Advice in Emergencies and to its current inquiry into the  safety of blood, tissue and organ screening. Her research interests include UK dietary exposure to BSE, autopsy surveillance for carriage of subclinical variant CJD, record-linkage studies for quantitative understanding of the morbidity and mortality of injection-related Hepatitis C and of drug treatment clients, randomized controlled trial of naloxone-on-release for reducing the very high risk of opioid-related death soon after prison-release and, more generally, the application of statistical methods to the criminal justice system’s treatment of drug-dependent offenders.



 

John BradleyDr John Bradley
Director of the NIHR Cambridge Biomedical Research Centre
Cambridge University Hospitals NHS Foundation Trust

John Bradley is Consultant Renal Physician and Director of Research & Development at Cambridge University Hospitals, where he is also Director of the NIHR Cambridge Biomedical Research Centre. He completed undergraduate training at Nottingham University and completed Research UK training and senior fellowships at Harvard, Yale and Cambridge Universities. Regional Specialty Adviser in Renal Medicine, Programme Director for Renal Medicine in the Eastern Deanery, member of the Joint Specialty Committee on Renal Disease and the Department of Health’s Renal Advisory Group, Special Adviser to Kidney Research UK and President of the Nephrology Section of the Royal Society of Medicine. He leads the NIHR BioResource, and is co-Chair of the NIHR Rare Diseases Translational Research Collaboration, and co-Director of the Cambridge-Yale research collaboration. He is Director of Studies in Medicine at Trinity Hall, University of Cambridge, and has written five textbooks on pre-clinical and clinical medicine. As an NIHR Senior Investigator e leads a research programme in vascular biology, with a focus on TNF signaling in the microvasculature. He is Editor of the British Journal of Renal Medicine.

 


 

James BrentonDr James Brenton
Senior Group Leader and Honorary Consultant in Medical Oncology,
Functional Genomics of Ovarian Cancer Laboratory
Cancer Research UK Cambridge Institute


James D. Brenton is a senior group leader at the Cancer Research UK (CR-UK) Cambridge Institute, University of Cambridge and leads the Functional Genomics of Ovarian Cancer Laboratory. He qualified in medicine from University College London in 1988 and trained in medical oncology at the Royal Marsden Hospital, Princess Margaret Hospital, Toronto and the Department of Oncology, University of Cambridge. He has been an honorary consultant in medical oncology at Cambridge University Hospitals NHS Foundation Trust since 2001. His PhD work was carried out at the Wellcome Trust/Cancer Research UK Gurdon Institute of Cancer and Developmental Biology and he held a Cancer Research UK Senior Clinical Research Fellow from 2001–2006 at the Hutchison/MRC Research Centre. His research focuses on the identification of prognostic and predictive markers for therapy in ovarian cancer and identifying mechanisms of drug resistance. His work has a particular emphasis on the genomic profiling of clinical samples to identify biomarkers of response. He is the chair of the Informatics Advisory Group for the national CR-UK Stratified Medicine Programme and was previously Vice-Chair of the CR-UK Biomarkers and Imaging Discovery and Development Committee. He is a member of the international Ovarian Tumor Tissue Analysis (OTTA) Consortium steering committee, the SGCTG Protocol Review Committee, NCRI ovarian cancer subgroup and the CR-UK Clinical Fellows Mentor Panel.

 


 

John BrimacombeDr John Brimacombe
Chairman
Linguamatics Ltd

John M. Brimacombe serves as Executive Chairman of the big data and health analytics platform provider, Linguamatics, which is the world leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support. Linguamatics I2E is used by top commercial, academic and government organizations, including 16 of the top 20 global pharmaceutical companies, the US Food and Drug Administration (FDA) and leading US hospitals. I2E can be used to mine a wide variety of text resources, such as scientific literature, patents, Electronic Health Records (EHRs), clinical trials data, news feeds, social media and proprietary content. A serial entrepreneur and investor, Brimacombe graduated in Law and Computer Science from Trinity College, Cambridge. In addition to his duties at Linguamatics he is a Partner at Sussex Place Ventures, the investment company of the London Business School and serves as a non-executive of multiple companies, both listed and privately held.

 


 

Anthony BrookesProfessor Anthony Brookes
Department of Genetics
University of Leicester

Anthony (Tony) is a Professor of Bioinformatics & Genomics at the University of Leicester, working on ‘knowledge engineering’ to bridge the divide between research and healthcare. In this context he is Director of the ‘Data-2-Knowledge-4-Practice’ Facility, a joint initiative by the University and the University Hospitals Leicester NHS Trust. He is experienced in disease and population genetics, DNA variation analysis, and data management for biomedical information, and in these areas has published >150 peer reviewed articles and reviews. He served two 3-year terms on the HUGO Council, co-founded the Human Genome Variation Society and the Human Variome Project, jointly designed the standard Observ-OM data model for gene-disease relationships, runs the world’s largest open GWAS database (GWAS Central), and recently created a new platform for open data discovery between clinical genetics laboratories (Cafe Variome). Also awarded several biotech patents, launched two bioscience SMEs, and participates (often in a leadership capacity) in a range of EU, IMI, and national consortia projects.

 


 

 

Nick BrownNick Brown
Innovation & Technology Architect
AstraZeneca

Nick joined AstraZeneca in 2000, working within drug project teams developing software to analyse thousands of experimental microarray data points. In 2004, he became a team leader in Advanced Science & Technology Labs, managing large computational clusters (100TB+) and designing automated image algorithms to screen millions of high-throughput screening images per day. His passion for handling Big Data grew further in 2007 focusing on identifying new disease areas for New Opportunities to pursue, through drug repositioning, in-licensing and acquisitions. Here Nick worked closely with external partners to develop business intelligence applications through designing an internal search based platform with >60 million scientific documents. Most recently Nick leads an IT team (EMEA) to rapidly evaluate and prototype novel approaches with external biotechs, startups and research labs, to foster new innovations into AstraZeneca.

 


 

Barry-Burles-212x300Mr Barry Burles
Consultant
Health Analytics

Throughout his career, Barry has been working with data to transform the performance of both large research driven businesses such as Dalgety plc and many small innovation lead companies. Amongst others, he has built technology lead diagnostic imaging businesses in teleradiology, pathology and EBCT, each of which uses large amounts of data. He has worked in primary care in the NHS through the Gateway to Leadership initiative, driving integrated care and changes in condition management. change. Having been involved from the outset, he has recently been developing Health Analytics. Their state of the science analytical software, called Snova, makes apparent in an easy to understand and transparent manner all that is happening across a local health economy. A complete electronic patient record for every patient is created by combining data in a common data warehouse from all the available sources within primary, secondary, social and community care, all within Caldicott 2 guidelines. This enables effective integrated care and transformational strategic planning, delivering enhanced care for less cost.


 

Jonathan BurroughsMr Jonathan Burroughs
CEO
Creative Places
CEO of Creative Places, consultant advisors to the Cambridge Biomedical Campus expansion project. Specialist advisor on the creation of business environments that help enhance innovation and enterprise. Keen to help grow the Cambridge Biomedical Campus community and enhance its effectiveness.

 


 

Ludovic Chassin- FaceDr Ludovic Chassin
Data Co-ordinator, Clinical Resource Office, University Department of Paediatrics
University of Cambridge

Ludovic obtained a PhD in Measurement and Information in Medicine from City University (London) and has worked in academia, health care institutions and industry throughout his career. He rejoined the University of Cambridge in January 2014 to work as a Data Co-Ordinator working on several projects related to the development of diabetes. Earlier in his career, Ludovic carried out research into the effect of exercise on glycaemic control in Type 2 diabetes patients, and lectured at the Sports Science Department of the University of Greenwich. Prior to that, he was involved in computer simulation for testing control algorithms fitting in automated insulin delivery devices in development. He also worked in public health at the Nuffield Trust where he was involved in predictive modelling, and in the management and analysis of large data sets of routinely recorded administrative and clinical data.

 


 

Afzal ChaudhryDr Afzal Chaudry
Lead for IT and Consultant Nephrologist
Cambridge University Hospitals NHS Foundation Trust

Afzal Chaudhry is a Consultant Nephrologist as well as the Chief Clinical Information Officer / Lead for the eHospital programme and NIHR Biomedical Research Centre Lead for Informatics at Cambridge University Hospitals. He is also the Chair of the Renal Association Terminology Committee working with the NHS HSCIC on the coding of renal disease; represents secondary care on the NHS England Standardisation Committee for Care Information; and chairs the UK Renal Data Collaboration project, incorporating the UK and Scottish Renal Registries; their equivalents from Northern Ireland and Wales, the British Association of Paediatric Nephrologists, the Renal Rare Disease Registry, PatientView and NHS Blood & Transplant, all working towards standardising and harmonising data flows in the field of renal medicine. He has > 50 peer reviewed papers, many in the field of biomedical informatics relating to autoimmunity and transplantation and has authored a number of bespoke software applications including novel algorithms related to organ / stem-cell HLA matching as well as a first-of-its-kind interactive online data visualisation portal for the Renal Registry.


Alastair CompstonProfessor Alastair Compston
Professor of Neurology, Department of Clinical Neurosciences
University of Cambridge
Alastair Compston is Professor of Neurology and Head of the Department of Clinical Neurosciences in the University of Cambridge. His research focuses on the clinical science of human demyelinating disease with contributions to the genetic epidemiology, immunology and neurobiology, and treatment and repair of multiple sclerosis. The work that he has led from Cambridge over the last 25 years led in 2013 to a EU product licence and subsequent NICE approval for Alemtuzumab as a first-line drug for relapsing-remitting multiple sclerosis. In 2002, he co-founded the International Multiple Sclerosis Genetics Consortium which has since identified approximately 200 risks variants for susceptibility to multiple sclerosis. He is currently developing a new research programme on the functional genetics of progressive multiple sclerosis. All of this work has depended on large data sets and international collaboration.

 


 

John CruickshankMr John Cruickshank
Director
Health ICT Consulting Limited
John Cruickshank specialises in strategic advisory work in health IT and digital health, working with government, healthcare, life sciences and industry clients committed to make strategic use of information and digital technologies. John specialises in interpreting complex policy agendas into practical, deliverable strategies leading to clinical improvement, better patient care and commercial success. John is also a partner in The IT Health LLP, through which he collaborates with other IT health professionals to deliver consulting services to the NHS, independent and private sectors.Since 2010, John has been responsible for launching and authoring six major reports published by the influential 2020health think tank. The reports have covered a spectrum of nationally significant issues across IT, telehealth and electronic health records and have measurably impacted government policy.Prior to his current roles, John held leadership positions in the healthcare practices of major consultancies and systems integrators. Through his 30 years’ experience in the field, John has gained deep insight of NHS culture, processes, people and systems and personally advised over 100 different NHS Trusts on IT strategies. He was an integral member of the core project teams that developed two published NHS IT strategies in the 1990s.

 


 

Isabelle de ZegherDr Isabelle de Zegher
Senior Director, Clinical Information Management
PAREXEL Informatics
Isabelle de Zegher, MD, MsC, is Senior Director Clinical Information Management at PAREXEL Informatics where she is responsible for Clinical Data Standards and Scientific Data Warehouse. She worked in pharmaceutical development for 14 years at Novartis, UCB and Cap Gemini Life Sciences consulting, after working for 10 years in the field of Health Care IT at Cap Gemini and in a Belgium SME. She has extensive experience in health information technology, data standards, data integration and semantic interoperability in clinical research. She used to chair the EFPIA task force on EHR integration and served on the CDISC Board of Directors for 3 years. She is co-chair of the PhUSE – FDA CSS working group on Emerging technology.

 


 

Chess DenmanChess Denman
Medical Director
Cambridgeshire and Peterborough Mental Health Trust (CPFT)

 

 

 


 

ProfEisen_H_2056_email-199x300Professor Tim Eisen
Professor of Medical Oncology, Department of Oncology
University of Cambridge
I trained in medicine at the Middlesex Hospital Medical School, London and University of Cambridge School of Medicine and graduated MB BChir in 1986. I completed 4 years of general medical training and became a member of the Royal College of Physicians (UK) in 1990. Between 1991 and 1995 I was a clinical research fellow at the Marie Curie Research Institute in Surrey. During this time I completed a PhD on the molecular biology of melanoma. Following this I trained as a medical oncologist on the Senior Registrar rotation of the Royal Marsden Hospital, London and Surrey. I received my Certificate of Completion of Specialist Training in Medical Oncology in 1997. I became a fellow of the Royal College of Physicians in 2002. In March 1998 I was appointed as Senior Lecturer in Medical Oncology at University College London where I developed special interests in the treatment of kidney cancer, melanoma and lung cancer. In February 2001 I took up a new post as Senior Lecturer in Medical Oncology at the Institute of Cancer Research and the Royal Marsden Hospital. My clinical responsibilities include the management of kidney cancer, melanoma and lung cancer. I was appointed chairman of the NCRI Lung Clinical Studies Group in 2004. I was appointed as Professor of Medical Oncology at Cambridge in December 2005 and aim to take up my post in 2006.

 


 

Patrick FarrantMr Patrick Farrant
Partner
Taylor Vinters
Patrick is a partner and head of the commercial and technology team at Taylor Vinters. Patrick is a commercial lawyer based in Cambridge and London. He specialises in the exploitation of intellectual property across a range of technologies, in particular life sciences. He has developed a detailed knowledge of the interface between the public and private sector and works expensively with high growth, entrepreneurial businesses Patrick advised Discuva on its transformational deal with Roche involving a $16 million upfront and research fees and payments on multiple programmes of up to $175 million per product. He advised Pulmagen on their $500 million collaboration and licensing deal with AstraZeneca and Heptares on its $180m deal with AZ. His team advised on over 100 fundings in 2013 raising over £125m. Patrick advised Index and XO1 on the licence-in from Cambridge Enterprise as part of Index’s $11m investment in XO1. He is recommended as a leading intellectual property lawyer in both the Chambers Guide to the Legal Profession and Legal 500. Patrick has both Swiss and English passports and speaks fluent French.


Flanders DavidDr David Flanders
Biotechnology Executive: CEO, Interim, Consultant
David Flanders Consulting
David is an independent life science executive and manager with 25+ years’ international experience in genomics, bioinformatics and related fields, delivering complex technology projects and products to the pharmaceutical and biotechnology industries. This includes: running an international genomics database at Stanford; supplying software to Celera for their human genome efforts when at Lion; and, recently, as CEO of Eagle Genomics where he led fund raising and company growth for this big data and cloud computing Cambridge-based company.

 

 


 

BlankDr Robert Frost
Policy Director, Medical Policy, Office of the Chief Medical Officer
GlaxoSmithKline

Rob is Policy Director within GlaxoSmithKline’s Office for the Chief Medical Officer (CMO). The CMO is the ‘voice of the patient’ within GSK, leading the culture and governance framework to place the interests of the patient at the centre of research, development and commercialisation of medicines. As part of the Medical Policy group, Rob develops internal policies and GSK external positions in areas where the CMO has primary responsibility including general medical governance, medical ethics and integrity and patient safety. Since joining GSK, Rob has supported the development of new transparency commitments around disclosure of clinical trial information, including the clinicalstudydatarequest.com initiative to provide external researchers with access to anonymised patient level trial data. He has also worked closely on topics relating to data privacy and ethics, including ongoing revisions to European data privacy legislation. Prior to joining GSK, Rob worked at the UK Academy of Medical Sciences on a series of policy projects addressing issues of medical science and healthcare in their wide scientific and societal context. This work included leading the secretariat for the Academy’s review of the regulation and governance of health research, which informed the creation in 2011 of the Health Research Authority.

 

 


 

 

Rowena Gardner

Ms Rowena Gardner
Company Secretary
BioIndustry Association (BIA)

Rowena is an experienced consultant, with background in operations, business administration and communications within organisations of varying sizes and types (public (listed LSE/NASDAQ), private and not-for-profit). Rowena has worked across a range of industries although she is currently focused on supporting the life sciences sector.  Rowena has held various positions within the BioIndustry Association (BIA) including Chief Operating Officer and currently holds the position of Company Secretary.  Prior to her work with the BIA she was Director of Corporate Communications at Cambridge Antibody Technology (now MedImmnune, the biologics R&D arm of AstraZeneca).

 


 

Alison HallAlison Hall
Programme Lead (Humanities)
PHG Foundation

A qualified lawyer, Alison also has experience in nursing and medical ethics. Her work at the PHG Foundation contributes legal and ethical expertise in policy development, particularly the need for adaptation to consent, data protection and feedback procedures in the light of new technologies. Her work also covers the regulation and governance of human tissue and data as well as wider debates about the implications of genomics and personalised medicine on health systems, services and individual behaviour. She is leading the Realising Genomics Project which addresses the clinical implementation of whole genome sequencing technologies. Many of the challenges associated with the use of these technologies concern the regulation and infrastructure for big data. She also works on ethical, legal and social issues arising from the regulation of genetic tests and stratified medicine. Alison also serves as a lay member of Cambridge South Research Ethics Committee.


BlankNina Hallowell
Social Science and Ethics Consultant

Nina Hallowell is a medical sociologist with qualifications in bioethics. She now works as an independent research consultant, but has previously worked at the Universities of Cambridge and Edinburgh, Newcastle University and the Institute of Cancer Research. She has worked on a variety of projects that have looked at the socio-ethical implications of implementing genetic and genomic technologies into clinical practice for both patients and healthcare providers, with a particular focus upon cancer genetics. She is currently involved in projects at Institute of Public Health and the PHG Foundation in Cambridge and at Ethox at the University of Oxford, which look at the clinical use of whole genome sequencing.


Mark Hammond Dr Mark Hammond
Partner & Managing Director
Accenture Life Sciences

I am the Managing Director responsible for Accenture’s Life Sciences’ R&D Hub in the UK, with over twenty years’ experience in the pharmaceutical industry. My main focus is on the interface between business and information and in optimizing the capture, management and use of information to drive business innovation, decision-making and efficiency in R&D. In recent years my work has focused on the impact of both the changing business model on how (and what) data is captured and consumed, and how in turn the increasing amount, type and source of available data can drive different business models. The emergence of “personalised” medicines, the blurring of the lines between R&D and Commercial, “in-life” trials, value management, and going “beyond the pill” into patient support services are some examples of where big data can impact the pharma and healthcare delivery model.

 


 

James HawkinsJames Hawkins
Director of Programme Delivery
Health and Social Care Information Centre

James joined what was the National Programme for IT in 2003 from Deloitte Consulting. He has over twenty years’ experience of working in programme environments spanning both the public and private sector. During that time he has worked on a number of high profile change programmes including the introduction of the London Congestion Charging Scheme, the NHS Summary Care Record, and the delivery of a single national patient demographic database for the NHS. In 2011, James took a year out from the NHS to be Head of the Security Workforce within the London Organising Committee for the Olympic Games. James returned to the NHS in 2012 to assist NHS England to scope the care.data initiative to help unlock the potential of data within the NHS. Since July 2013 he has held the position of Programmes Delivery Director within the Health and Social Care Information Centre, where he is responsible for delivering 18 major projects and programmes across the health and social care system. James is also currently undertaking the Cabinet Office’s Major Project Leadership programme.

 

 

 


 

Kurt Hertogs

Dr Kurt Hertogs
Platform Innovation & Incubator Strategy Leader, Johnson & Johnson Innovation Centre
Johnson & Johnson Innovation Centre

 

 

Kurt Hertogs has been trained as a Pharmacist, and holds a PhD in Pharmaceutical Sciences from the Catholic University of Leuven. He is a member of the Board of Directors of Janssen Pharmaceutica NV, and the Janssen Campus Belgium Management Team. He joined Tibotec – at start up- in 1994 and has held a variety of positions in research and early development. He was actively involved in the discovery and pharmacological profiling of Tibotec’s anti-infectives portfolio (Prezista (TMC114), Intelence (TMC125), Edurant (TMC278), Situro (TMC 207) and Simeprevir (TMC 435). Since 2008, Kurt has been heading, respectively, both the European, ànd Global Enabling Research Capabilities at Janssen R&D supporting the discovery product portfolio across Janssen’s five therapeutic areas of strategic focus. In that role he was a member of the Janssen R&D Senior Leadership Team and the Janssen R&D Operational Management Committee. Kurt took on the role of Platform Innovation and Incubator Strategy Leader at the Johnson & Johnson Innovation Center London. In that role he represents all Janssen R&D platform groups to both attract new technologies, ànd offer Janssen expertise and capabilities to third parties through the J&J Innovation Center. In addition he develops a strategy for creating Janssen Innovation Incubators across Europe, in concert with local research institutions and investors. In our collective pursuit of discovering ànd developing transformational patient-centric solutions for diseases with a high unmet medical need, these incubators will drive the interaction and exchange of knowledge, and capabilities, between Janssen’s pharmaceutical R&D expertise and the broader academic and biotech ecosystem in Europe. Kurt has a passion for Entrepreneurial Innovative Science & Technology, and how to put it at work in our fast changing Healthcare Ecosystem. He is a strong believer ànd advocate of multi-functional collaboration across many scientific domains and organizations to drive transformational science, innovation ànd value creation for patients in need.


 

Tim Hubbard

Professor Tim Hubbard
Head of Bioinformatics
Genomics England

Professor Tim Hubbard is Director of Bioinformatics for King’s Health Partners and Head of the Department of Medical & Molecular Genetics at King’s College London. He is also Head of Bioinformatics at Genomics England which is carrying out the 100,000 genomes project. He was formerly Head of Informatics at the Wellcome Trust Sanger Institute where he was one of the organisers of the sequencing of the human genome and co-founder of Ensembl. He leads the GENCODE project that generates reference gene sets for human and mouse. He is actively involved in efforts to improve data sharing in science, develop open access publishing resources and plan for the adoption of genomic medicine. He is a member of the UK Expert Advisory Board on Data Access (EAGDA) and chair of the Advisory Board of Europe PubMedCentral. He was a member of the OSCHR e-health board which advised on the research use of electronic medical records, leading to the development of CPRD and the creation of the Farr institute, and working groups of the Human Genomic Strategy Group (HGSG), whose report led to the creation of the 100,000 genomes project.


 

BlankCatherine Hutton
Chief Executive
Research in Real Life UK Ltd

 

 

 


 

 

BlankRoger James
IT Director – NIHR Rare Diseases Translational Research Collaboration
University of Cambridge

 

 

 


 

Kevin JohnsonKevin Johnson
Managing Director
Johnson Leigh

 

 

Kevin has worked in technology-enabled innovation and large-scale change for 30 years, through senior operational, Board, consultancy and trusted advisory roles, in many different sectors, countries and contexts. This has included working with some of the world’s most impressive organisations, across business (including Cisco, Accenture, AstraZeneca), academia, health, care and more.    With Cisco (world-leader in networked systems), Kevin served as Board Member UK&Ireland, and led national and global practices for Cisco’s strategy and innovation team.  This included providing Board-level insight, challenge and support to many customer and partner organisations, as well as Cisco itself, to help them thrive in a highly connected and digital world.  He has chaired international forums globally, presented widely and published variously.  Kevin now supports a range of organisations with their innovation, growth and digital strategies, in non-executive, advisory and independent consultancy capacities.  Harnessing big data, along with other highly-relevant and disruptive global trends, is an increasingly prominent feature of each.

 


 

Michelle JonesMichelle Jones
Senior Director, Operational Strategy and Planning – Modeling
Covance Clinical and Periapproval Services Limited

After graduating from the University of Kent in Canterbury with a B.Sc. in Mathematics and Computer Science, Michelle completed her M.Sc. in Statistics with Applications in Medicine at the University of Southampton in 1989. In 1989, Michelle started her career within the pharmaceutical industry as a Statistician, where she was responsible for the analysis and reporting of Phase II – IV clinical trials, providing the integrated summaries of safety and efficacy for NDA/MAA regulatory submissions and presenting these findings at the FDA Advisory Committee Meeting. In 1996, Michelle joined Covance as a Principal Statistician and acquired more experience in designing and analysing trials across a wide variety of therapeutic areas and phases of development. In her various roles within Biometrics at Covance, Michelle was responsible for the statistical deliverables on all her projects and the management of all Biometrics activities in her later projects. In 2001, Michelle created the Project Informatics Group (now known as the Operational Strategy & Planning – Modeling Team). This is a global, multidisciplinary team, responsible for forecasting patient recruitment timelines, timelines for endpoints occurring and volume of data. The team supports other business units and functions by providing estimates which are used in the forecasting of laboratory kit volume expected at the various depots and the forecasting of Investigator Grant Payments as well as the current liability. This team also supports the creation of innovative outputs derived from internal and external data streams, as well as providing the metrics outputs for the FoQuS reviews.

 


 

 

Peter JonesProfessor Peter B. Jones
Professor of Psychiatry & Head of the Department of Psychiatry
University of Cambridge

Peter Jones is Professor of Psychiatry & Head of the Department of Psychiatry at the University of Cambridge.  He is a board member of Cambridge University Health Partners and directs the NIHR Collaboration for Leadership in Applied Health Research & Care (CLAHRC) for Cambridgeshire & Peterborough. Peter’s research concerns the epidemiology of mental illness, particularly the psychoses, early life course influences on adult mental health and illness, and the interface between population-based and biological investigations and explanations, including genetics. He also works in treatment research with randomised trials of drug and psychological treatments for psychotic illness. Clinically, Peter works as an honorary consultant to the Cambridgeshire & Peterborough Foundation Trust’s early intervention service for young people with first episode psychosis (CAMEO http://www.cameo.nhs.uk/ ). He has been a non-executive director of a specialist mental health NHS trust (2001-2005), served as a co-opted expert on the Advisory Council on the Misuse of Drugs consideration of the legal status of cannabis (2005 & 2008) and coordinates the Royal College of Psychiatrists Early Intervention Network. He became a NIHR Senior Investigator in 2010.


 

Rachel JonesDr Rachel Jones
Innovation Specialist
Digital Economy Catapult

Rachel has over 20-years’ experience in strategic digital design. Rachel is Innovation Specialist for the Digital Catapult and the Knowledge Transfer Network, part of the Technology Strategy Board, and leads on initiatives for the Internet of Things, Big Data and Digital Health. Rachel also runs a digital design agency called Instrata which has clients such as Microsoft and Vodafone, NGOs such as Oxfam and the BBC, and many start ups. Rachel is a Design Associate for the Design Council and Visiting Professor at Nottingham Trent University. Rachel has worked in both R&D settings (Xerox EuroPARC, Microsoft Research) and design settings (Sapient, Instrata). Rachel has over 30 international academic publications and 10 patents. Rachel is particularly interested in areas that involve design and healthcare and is developing BeCurious, a mobile support framework for chronic disease self-management.

 


 

Misha KapusheskyDr Misha Kapushesky
Chief Executive
Genestack

Most recently team leader in functional genomics at the European Bioinformatics Institute, where his team developed bioinformatics data systems for academia and industry, such as Gene Expression Atlas. Misha Kapushesky has first-hand experience in dealing with big data in genomics and has participated in and led international consortia applying bioinformatics to medical research. Before joining the EBI in 2001, he worked at several high-tech startups in the area of large-scale data search and processing around Boston, USA. He was educated at Cambridge (Ph.D., Genetics), Oxford and Cornell Universities (B.S., Mathematics).

 

 


BlankMr Neil Kipling
CEO
IDBS

 

 

 

 

 


BlankChristopher Larminie
Director Computational Biology, QSci Computational Biology(UK), RD Projects Clinical Platforms & Sciences
GlaxoSmithKline

 

 


 

BlankStuart Lawrence
Account Chief Technologist
Hewlett Packard Enterprise Services

 

 

 

 


 

Maggie MassamMrs Maggie Massam
Head of Business Development
Clinical Practice Research Datalink

Maggie joined the Clinical Practice Research Datalink (CPRD) in July 2012 to establish and lead a new Business Development team as the organisation began a period of significant growth. Maggie has worked in healthcare and the biopharmaceutical industry for more than 25 years, her career beginning in the NHS as haematologist. She has held senior positions in pharmaceutical marketing, advertising, medical communications and clinical research. Maggie’s experience includes 12 years in the US. As Senior Vice President for Global Marketing at Abraxis BioScience she led the successful EU launch of Abraxane and prior to CPRD was Business Development Director at Quintiles.


 

Patrick MaxwellProfessor Patrick Maxwell
Regius Professor of Physic & Head of the School of Clinical Medicine
University of Cambridge
Professor Patrick Maxwell undertook postgraduate clinical and research training in nephrology and general medicine at Guy’s Hospital and in Oxford. He was appointed as University Lecturer and then Reader at the University of Oxford. In 2002 he moved to the Professorship of Nephrology at Imperial College, followed by the Chair of Medicine at University College London in 2008. He was appointed Regius Professor of Physic and Head of the School of Clinical Medicine of the University of Cambridge in 2012. Professor Maxwell has served on a number of national grant committees and holds a Wellcome Trust Senior Investigator Award. He was elected a Fellow of the Academy of Medical Sciences in 2005, and was its Registrar from 2006 to 2012.

 


 

Peter McCallumDr Peter McCallum
Head of IT & Scientific Computing
CRUK Cambridge Research Institute

I am the Head of IT & Scientific Computing for the Cancer Research UK Cambridge Institute, where I am responsible for all aspects of computing from network infrastructure to scientific databases and HPC provision. As a small team supporting many data-centric research groups, we are interested in providing efficent, scalable IT solutions based on adapatable standard technologies. Previously, I have worked as a developer and consultant building distributed systems for the pharamaceutical and genomics industries, and for the European Bioinformatics Institute and Edinburgh Parallel Computing Centre. I originally trained in Chemistry and Biochemistry at Edinburgh and Glasgow Universities.


 

Paul McGheeMr Paul McGhee
Director, Norfolk and Suffolk Node
Eastern Academic Health Science Network

Paul McGhee is an innovation specialist with global experience at director and CXO level of creating new start-up organisations in the media, telecommunications, product development and healthcare sectors. Most recently he has worked in Cambridge and Norwich helping to create a series of publicly funded organisations with the collective aim of facilitating innovation in the NHS, the latest of which was the Eastern Academic Health Science Network. His skill-set includes marketing, financial analysis and corporate strategy. His interests in the “Big Data” field include the development of non-clinical innovations in the NHS for integrated care, especially improving the interface between citizens and providers of service through data sharing and the use of consumer technologies such as NFC, IoT, White Space and sensor networks. He is also currently interested in the relationship of technological innovation to corporate governance and the democratic oversight of the NHS – and area which he believes is very urgently in need of improvement.

 


 

Janet MesserDr Janet Messer
Programme Director – HRA Approval
Health Research Authority
Janet Messer is Programme Director for HRA Approval at the Health Research Authority, implementing a new integrated system for approval of health research in England over the next two years. She also works collaboratively with a wide range of partner organisations to fulfil the HRA’s aims to make it easier to do good quality ethical research in the UK. Prior to working at the HRA she was Head of Research Management and Governance at the NIHR Clinical Research Network, where she was responsible for a major change programme to improve the NIHR Coordinated System for gaining NHS Permission. She has a PhD in biochemistry from University of Cambridge, followed by many years’ experience of clinical research in the pharmaceutical industry. Previous roles in NHS R&D include running the Integrated Research Application System (IRAS) and leading a number of national initiatives to improve NHS research management through the NHS R&D Forum.

 



Paul MilliganDr Paul Milligan
Senior Application Specialist
Linguamatics Ltd

Paul Milligan is a Senior Application Specialist and has been with Linguamatics since 2005. In this role, he works with customers in the pharmaceutical, biotechnology and healthcare industries to derive maximum benefit out of I2E, the Linguamatics Natural Language Processing-based text mining software. In additional, Paul has responsibility for the I2E Web Services API, to allow integration of text mining capabilities into large-scale workflows. He has worked on many customer projects, including analysis of historical pre-clinical records, assisted diagnoses from radiograph descriptions and semantic annotation for enterprise search. Paul has a doctorate from University of Cambridge in computational drug design where his work involved developing algorithms to optimize combinatorial libraries for protein-ligand interactions. After graduating, Paul worked in the Cambridge biotech sector, at De Novo Pharmaceuticals and Purely Proteins. In these companies, he developed and used bioinformatics and chemoinformatics tools for processing of diverse large-scale databases, including PDB, compound registries and PubMed.

 


 

chris-molloyChris Molloy
Chief Executive
RSA Search & Selection[/ABC]

I have over 20 years’ experience of international Life Sciences across pharmaceuticals, biotechnology, informatics and start-up sectors. I started my scientific career at Glaxo in 1990, leading multiple in-house and collaborative research projects. I was also a pioneer in the introduction of industrial IT, process and automation solutions to meet the needs of drug discovery, dramatically improving the productivity and quality of research efforts worldwide. Leaving GSK in 2004 I moved into biotech and to Asia as Chief Operating Officer of MerLion Pharmaceuticals, a biotechnology company headquartered in Singapore. Here I was responsible for business planning, operations, business development, fundraising and M&A. Returning to the UK in 2008 I became VP Corporate Development at IDBS, a high-growth international software company focussed on improving R&D and Healthcare organisations. I was also a Non-Executive Director on the Board of the RSA group. I also hold a number of additional Boards, technology and scientific advisory roles.


 

JMurphy-2Dr John Murphy
Director Partnership to Advance Clinical electronic Research –PACeR
Quintiles Clinical Informatics Innovation

 

 

John Murphy Heads Clinical Informatics & Analytics within the Innovation Group at Quintiles. Eight years ago he founded and has been working with Pfizer, Merck, J&J, Roche, Bayer and other pharmaceutical companies and a nationwide academic hospital-physician-patient cloud-based health network to create a uniform environment for the conduct of basic, clinical and medical outcomes research. The Partnership for Advancing Clinical Electronic Research (PACeR) is a 501c3 non-profit collaboration that has been operational for five years and has deployed a nationwide cloud-based clinical research platform that is being used to automate multi-site trials and quality and outcome studies. When he is not working at Quintiles he is a founder and active board member of Sylvan Road Capital and Havenbrook Homes, a multi-billion dollar family real estate hedge fund. Prior to joining Quintiles, his career in drug development includes positions as: Senior Executive Advisor to the Booz, Allen & Hamilton and Booz & Company healthcare and pharmaceutical and lifescience R&D partnerships; Senior Vice President at Pharsight Corporation (16b Officer), and; Senior Vice President and CIO at Curagen (16b Officer), a genomic-based drug development company. His teams developed Genescape, an advanced platform to industrialize the identification and validation of targets & Leads and the development of monoclonal and protein therapeutics to cure disease. The platform provided a collaborative electronic environment for small molecule development at Bayer and large-scale sequencing for most of the major pharmaceutical companies. In addition to supporting successful development of several drugs, he led teams that developed predictive hepato-genomic insilico chips for prediction of drug toxicity and the 454 Sequencing Platform. His career in Clinical Informatics includes: Founder and CEO of Just Medicine Technologies, Incorporated and SVP of Clinical Software Engineering (16b Officer) of Community Health Computing (CHC), a public company that acquired Just Medicine. In the medical care and delivery space he has served in a variety of positions including Chief Executive Officer within NYS academic medical centers and while in medical school founded a successful medical device and instrument company that he sold to a group of public corporations after 15 years of profitable growth.His academic career includes faculty positions at MIT, University of Buffalo Law School and Columbia University. As a national policy advisor he served on a White House-based National Commission and was responsible for policy recommendations for the federal funding of undergraduate and graduate medical education. He has co-authored two books and hold patents on a variety of medical devices and clinical software applications. In 2000, he was recognized by Columbia University and awarded its Medal of Distinction for his contributions in the fields of medicine, technology & law. He has undergraduate and graduate degrees from Columbia College, Columbia University Faculty of Medicine-Columbia University School of Public Health (Epidemiology) and post graduate education at Harvard: Managed Care Computing and Yale School of Organization & Management: Finance.

 


 

Sridevi NagarajanDr Sridevi Nagarajan
Senior Data Manager, Cambridge Clinical Trials Unit
Cambridge University Hospitals NHS Foundation Trust

As a Biologist turned Health Informatics professional, I have demonstrable success in dealing with variety, veracity, velocity and volume of data. In a number of data-driven project engagements, I have led the shift from conventional data collection and analysis methods to streamlined electronic collection and established a centralized “single-view-of-truth” for the end clients. In addition to down-stream quality control, my expertise includes up-stream data quality assurance, as my stake-holders comprised policy makers like MHRA, PIAG, ONS and audit authorities. I have architected, designed and implemented biological-data applications and integrated with external big-data systems through service-based methodologies like Service Oriented Architecture. I played key role in building strategy for optimization in data integration and analytics for various projects, and also involved in data-mining in a large-randomized trials and observational studies for cardiovascular diseases. As part of continuous-improvement, I introduced and executed SIPOC analysis to benchmark process metrics. During last 16 years, I have been part of knowledge Management projects and programs of various Laboratories, Research Institutes, Universities, Pharmaceutical companies and CRO in Asia, USA and UK. My experience covers strategic positioning of Information System landscape, data governance, distributed data architecture, information lifecycle management, enterprise content management analytics and data visualization. I have contributed to ideation, grant application submission, project planning, analysis, construction, delivery and operational support of medical- informatics solutions for customer requirements and proactive research problems.

 


 

Fiona NielsenMs Fiona Nielsen
Chief Executive
DNAdigest
Fiona Nielsen is a bioinformatics genetics scientist with a background in computer science and software development. Her work in bioinformatics started with theoretical protein structure prediction and later moved on to epigenetics as a junior researcher at the NCMLS in the Netherlands. At Illumina in Cambridge, UK, she developed tools for analysis and interpretation of DNA sequencing samples in the Data Analysis for Collaborations group to interpret clinical samples for patient diagnostics for cancer and other genetic diseases. Since March 2013 she has been working as CEO of the not-for-profit organisation DNAdigest working to address the issues of data sharing of human genetics data for research, working to promote and enable more efficient mechanisms of data discovery and data access. Her work is powered by a passion to drive the genomic revolution for the benefit of patients. Fiona Nielsen was nominated for the 2013 WiSE awards for innovation and entrepreneurship by the Association of Women in Science and Engineering.


Steve O'RahillyProfessor Sir Stephen O’Rahilly
Co-Director, IMS; Director, University of Cambridge Metabolic Research Laboratories; Director, MRC Metabolic Diseases Unit
University of Cambridge

Stephen O’Rahilly graduated in Medicine from University College Dublin in 1981.  From 1982 to 1991 he undertook postgraduate clinical and research training in general medicine, diabetes and endocrinology in London, Oxford and Harvard.  In 1991 he obtained a Wellcome Trust Senior Clinical Fellowship and established his laboratory at the University of Cambridge.  In 1996 he was appointed to a newly created Chair of Metabolic Medicine and in 2002 to the Chair of Clinical Biochemistry and Medicine at the University of Cambridge.  He is the Co-Director of the Wellcome Trust-MRC Institute of Metabolic Science and Director of the MRC Metabolic Diseases Unit.  His research has been concerned with the elucidation of the basic causes of obesity and Type 2 diabetes at a molecular level and the translation of those discoveries into improved diagnosis and therapy for patients.  His work has uncovered several previously unrecognised genetic causes of these diseases including some that are amenable to specific treatment.  He has won many awards for his work including the Society for Endocrinology Medal, the European Journal of Endocrinology Prize, the Novartis International Award for Clinical Research in Diabetes, the Clinical Investigator Award of the Endocrine Society, the Heinrich Wieland Prize, the Rolf Luft Award, the Feldberg Award, the Society for Endocrinology Dale Medal, the InBev Baillet-Latour Prize for Health and the Ulysses Medal.  He was elected to the Academy of Medical Sciences in 1999, to the Royal Society in 2003, to the US National Academy of Sciences in 2011 and is an Honorary Member of the German Society for Internal Medicine.  He has received honorary doctorates from the Universities of Dundee, Warwick and Buckingham and from University College Dublin.  In 2013 he was appointed a Knight Bachelor for services to medical research.  He has a continuing commitment to clinical practice and the teaching of medical students.  He has made important contributions to the development of infrastructure for clinical research on the Addenbrooke’s campus.  He has been a successful mentor of young scientists and clinician-scientists.  He has contributed more generally to UK science through his Chairmanship of the Wellcome Trust Clinical Interest Group, the Medical Research Society and of the MRC Translational Research Overview Group; through his membership of the MRC Strategy Board and his service on the research advisory committees of several charities and companies.


 

Simon Oberst

Simon Oberst
Director of Development (Clinical)
CRUK Cambridge Research Institute

Simon Oberst is a Fellow of the Institute of Chartered Accountants of England and Wales and began his career in the City with firms which are now KPMG and PwC. He specialised in the taxation of international companies and high net worth individuals. After moving into the charity sector, he spent six years with Macmillan Cancer Support as Director of Improving Cancer Services, which was a strategic role interacting with the NHS and the Department of Health. His current role is Director of Clinical Development of the Cambridge Cancer Centre, working with colleagues within Cambridge University Hospitals and the CRUK Cambridge Institute on the Strategic Cancer Plan for Cambridge which embraces cancer biology, translational research and clinical excellence, and in particular plans for capital development of a new Cancer Treatment Centre on the Addenbrooke’s site. In his spare time Simon moonlights as a semi-professional singer, having been a member of the Monteverdi Choir for many years, after graduating as a choral scholar from Trinity College.


 

Willem OuwehandProfessor Willem Ouwehand
Professor of Experimental Haematology
University of Cambridge & Wellcome Trust Sanger Institute and NHS Blood and Transplant
[/ABC]

 

 

 

 

 


 

Cathy PrescottDr Cathy Prescott
Director
Biolatris

 

 


 

 

 

 

Carolyn ReadCarolyn Read
Research Governance Officer, School of Clinical Medicine
University of Cambridge
I have a Masters in Ethics of Medical Research and Biotechnology from Keele University and I am currently Chair of one of the local NRES Research Ethics Committees. In addition I sit on the University Research Ethics Committee. My role as Research Governance Officer is to advise all areas of the University including the Research Office, Legal Services, Insurance Office, and HR, and the Clinical School Computing Service on research governance related matters. I am responsible for research governance matters throughout the Clinical School and work closely with Cambridge University Hospitals NHSFT R&D office, Cambridgeshire and Peterborough NHSFT R&D office and the Cambridge Clinical Trials Unit.  I am also responsible for the Clinical School Information Governance Toolkit and work closely with the School IT team on all data issues relating to research.


 

Augusto-RendonDr Augusto Rendon
Head of Clinical Bioinformatics; NIHR Bioresource – Rare Diseases
University of Cambridge
I obtained a degree in Physics from the Universidad de los Andes in Bogota, Colombia. In 2001 I moved to the University of Toronto and completed a PhD in the Department of Medical Biophysics at the Ontario Cancer Institute working on both physical and biological strategies to improve the therapeutic efficacy of photodynamic therapy for the treatment of brain and prostate tumours. Since 2008 I have been working at the Department of Haematology at the University of Cambridge and at the MRC Biostatistics unit. I consider myself a quantitative biologist with a broad skill set in statistical genetics and genomics, bioinformatics and computational biology. I use these skills to discover new genes that regulate platelet formation and function and to understand the mechanisms by which these genes and processes are affected by DNA sequence variation in normality and disease. Since 2011 I lead the bioinformatics team involved in various projects including DNA sequencing based diagnosis of platelet and bleeding disorders, whole genome sequencing in rare diseases and targeted re-sequencing for fine mapping and rare variant discovery in GWAS regions. I also head clinical bionformatics for the NIHR Bioresource – Rare Diseases which aims at whole genome sequence 15,000 patients with rare diseases.

 


 

alessandro-riccombeni-portraitDr Alessandro Riccombeni
Senior Scientist
Genestack

Before doing research on regulatory genomics at UCL Cancer Institute, Alessandro Riccombeni studied comparative genomics of pathogenic yeasts in Dublin, Ireland. During this time he collaborated with Illumina in Cambridge, UK on predicting large structural variants. Prior to that he studied de novo originated oncogenes at the IFOM-IEO campus in Milan, Italy, and worked in the Carbohydrate Chemistry group at the University of Lisbon, Portugal. His experimental background gave him years of experience in seeing bioinformatics from a biologist’s point of view. He was educated in Ireland at University College Dublin (Ph.D., Bioinformatics) and in Italy at the University of Milan-Bicocca (B.S., Biotechnologies).

 

 

 

 


 

Sylvia Richardson

Professor Sylvia Richardson
Director
MRC Biostatistics Unit 

 

 


 

Peter SingletonMr Peter Singleton
Director
Cambridge Health Informatics

 

Peter Singleton is Director of Cambridge Health Informatics, specialising in the strategic use of information in healthcare, particularly privacy and confidentiality issues in UK and abroad. He has been involved in a number of EU projects (EHR4CR; VPH-Share & DebugIT) and conferences on the legal and ethical aspects of privacy. He led the ‘The Informed Patient’ project, which looked at patient information use across Europe. He has worked on a range of EHR and research-related projects in the UK on business models and information governance issues. He spent 5 years on the UK’s Connecting for Health project to implement a new generation of electronic health records in England. Previous work includes: Gaining Patient Consent to Disclosure (2001); the NHS Confidentiality Code of Practice (2003), NHS Information Governance Toolkit (2003/4), the Personal Information in Research Toolkit (MRC 2005-6), Public and Professional Attitudes to Privacy in Healthcare Data (GMC 2007) and Critical Issues for Electronic Health Records (Nuffield 2008). Peter trained as an actuary before moving into IT software development and management consultancy. Peter has an MA in Mathematics and MBA (Cambridge). He is an Honorary Senior Research Associate at University College London.


Mike SnowdenDr Mike Snowden
Head Discovery Research
AstraZeneca
Mike joined Glaxo Group Research in the UK in 1988 after completing a PhD and postdoctoral studies at Liverpool University. Recruited as a microbial biochemist and enzymologist, he worked initially on anti-infectives and then in the Cardiovascular and Respiratory areas where he led a number of early phase dyslipidemia and inflammation projects. In 2001 at the formation of GSK, Mike was appointed to head a cross therapy area group providing HTS and SAR screening support to the CNSP and Respiratory groups in the UK, joining the senior leadership team in the Respiratory business Unit to manage their early portfolio in 2005. Mike left GSK in 2010 to join Innovative Medicines and Early Development (IMED) at AstraZeneca as Head of Discovery Research. With groups in Sweden, the UK and the US, his current group focuses on internal and collaborative research to provide a comprehensive range of technical and translational activities to preclinical project teams including; HTS and SAR screening, X-ray crystal/biophysics support, statistics, bio-informatics, and bio-reagent generation and assay development capabilities.


 

Will SpoonerDr Will Spooner
CTO
Eagle Genomics

William Spooner is a seasoned operational bioinformatician with a track record of delivering tools for high-throughput genomics research. Having worked previously on Ensembl, BioMart, Gramene and WormBase at the European Bioinformatics Institute, the Wellcome Trust Sanger Institute and Cold Spring Harbor, his current focus is on making life easier for users of open source/data in commercial settings. His strategic thinking is driven by the huge opportunities for data analysis in the life sciences provided by the near simultaneous arrival of NGS and cloud computing.

 

 

 

 

 


 

Sally StandleySally Standley
Director of Service Innovation, Cambridge Biomedical Campus CUHP Integration Lead
Cambridge University Health Partners (CUHP)
Sally Standley is a Director at Cambridge University Health Partners (CUHP), one of six Academic Health Science Centres (AHSC) in the country. Her work includes supporting CUHP partners and other campus stakeholders in adopting an integrated approach to the development of the Cambridge Biomedical Campus (CBC). She is also the Director of Clinically Led Innovation at the Eastern Academic Health Science Network (EAHSN), one of 15 AHSNs nationally which are working to co-create wealth by closer working between the NHS and industry, and supporting the adoption and diffusion of evidence based best practice. Previous roles include leading the NHS Midlands and East Stroke Review 2012/13; service reconfiguration and service development across the eastern region in cardiothoracic services and long terms conditions; and working for 7 years as Chief Executive of South Cambridgeshire Primary care Trust; during the latter two of which she was also the Chief Executive of Cambridge City PCT.


 

Doug StewartDouglas Stewart
Head of Viral Challenge
Retroscreen Virology Ltd

Retroscreen Virology is a specialist research organisation with a focus on respiratory viral infection (HRV, Influenza and RSV), and conducts academic and commercial studies in healthy volunteers and patients who are inoculated with virus and treated with IMP, and/or examined and tested for disease progression. Future plans include diversifying into patient models, specifically asthma at this time. Douglas is head of the Viral Challenge units in Cambridgeshire and London (specialist quarantine facilities dealing with up to 30 volunteers at a time) and leads a team of clinical research physicians and health care professionals in conducting these clinical trials. A clinical research professional for over 12 years, his background is biochemistry, nursing and medical law, and he has worked as a Project Director, Head of Clinical Operations and Senior Director of PMO in CRO during that time. He is interested in developing collaborations with academia, industry and the NHS.”


 

Mark StrivensDr Mark Strivens
Managing Director
Biotransys Ltd[ABC]

Mark Strivens is an experienced informatician with a broad background spanning genomics, bioinformatics and data-systems in the life-sciences research sector. Through effective collaboration and forming strong working relationships at all levels of an organisation, Mark uses his wide multi-domain knowledge to deliver strategy and analysis that drives research and business forward. Before forming his informatics consultancy, Biotransys Ltd, Mark spent 20 years working at a senior level in both academic research (MRC, BCM) and commercial R&D in the UK and USA.


 

BlankMr Jim Sutherland
Account Executive
Hewlett Packard Enterprise Services

 


 

Pete ThackeryMr Peter Thackery
Sales Director
Hewlett Packard Enterprise Services

 


 

Aidan ThomasMr Aidan Thomas
Chief Executive
Cambridgeshire and Peterborough Mental Health Trust (CPFT)
Aidan Thomas has more than 30 years’ experience in the NHS and a long background in mental health. He joined CPFT from Norfolk and Suffolk NHS Foundation Trust where he was Chief Executive and successfully led the merger of Norfolk and Waveney Mental Health NHS Foundation Trust and the Suffolk Mental Health Partnership NHS Trust in 2012. Prior to joining Norfolk and Suffolk NHS FT in October 2009, Aidan was Chief Executive Officer at West Essex Primary Care Trust. Aidan is a former director of human resources and executive director of Lambeth Community NHS Trust. In 1995 he joined Essex and Herts Community NHS Trust as director of operations, and was appointed Chief Executive of Epping Forest Primary Care Trust in April 2000.

 


 

Simon-ThornberDr Simon Thorber
Director, Discovery Analytics Informatics and Innovation, R&D-IT
GlaxoSmithKline
Simon has been at GSK for over fifteen years, initially joining R&D, working in Genetics, Bioinformatics, and Cheminformatics, before joining R&D-IT. Simon now has a strategic role, focussed on the opportunity for new IT technology to provide better answers to R&D’s big questions of value.

 

 


 

BlankTim Thornton

Technology Architect

Accenture

Tim is a Technology Architect at Accenture, and has spent much of the past 7 years working on healthcare related projects both in the NHS and abroad, concentrating on mobility and infrastructure aspects. His focus has been on the delivery of improved outcomes using technology as a way of allowing clinicians to make better decisions and to involve patients in their own care management.

 

 


 

Claire-TrippClaire Tripp
Director of Operations
Papworth Hospital NHS Foundation Trust

 

 

 


 

Dr Tempest van SchaikTempest
Researcher
DNAdigest

Tempest has a strong and diverse background in biotech, from being South Africa’s first Biomedical Engineering graduate, to strengthening these skills with an Electrical Engineering degree, to a PhD in Bioengineering at Imperial College. Currently she is working as a Research Assistant with DNAdigest developing new mechanisms facilitating genetics data sharing for academia and industry.

 


 

Peter WainmanPeter Wainman
Associate
Mills & Reeve LLP

Peter is an IT and data protection lawyer.  He has advised on a number of major IT projects in the NHS relating to the use of patient data (including the Addenbrooke’s eHospital project).  Peter regularly advises on data sharing, data exploitation and the impact of the changing structures within the NHS on the use of data.

 


 

ChrisWalkerMr Chris Walker
Executive Director, European Regulatory Affairs Head
Amgen Limited
Chris is currently the head of International Regulatory Affairs for Amgen’s Non-Oncology product portfolio. This involves directing the regulatory strategy for the International region, management of a group of regulatory professionals, external engagement of Regulatory Agencies and management of appropriate regulatory systems. Chris has been with Amgen since 2005. Over this time, Chris has had several roles supporting both development and commercial products as well as working externally with regulatory agencies and trade associations. Before working with Amgen Chris worked as a regulatory professional at Bio Products Laboratory (BPL). In this role, Chris supported a range of biological products internationally (including the Middle East, South America, Far East and Europe). This role included clinical trial and marketing authorisation activities as well as leading the development of product packaging & risk assessments. During his time at BPL Chris also led the cross functional development activities for a product reporting directly to the CEO’s leadership team.Chris’ regulatory career spans 15 years. Prior to his regulatory career Chris worked as a research scientist in process development. During this time Chris was also an internal GMP & GLP auditor. Chris has an MSc in Regulatory Affairs (MSc RA) and BSc (Hons) in Applied Biological Sciences. Chris is a member of TOPRA (MTOPRA) and the Chartered Institute of Biology (MIBiol, CBiol.).


 

Jeanette-WalkerJeanette Walker
Project Director
Cambridge Biomedical Campus
After graduating in Law and French, Jeanette gained a Diploma in European Export Marketing from the University of Louvain in Belgium. She has since worked in a variety of international business development roles including seven years as Business Development Director at the Cambridge-based biotechnology industry group formerly known as ERBI, and as Project Manager for the East of England Stem Cell Network. In August 2009, Jeanette established lets cell it.com limited, a company specialising in the development of web portals for the life sciences sector including www.biopharmamarket.com which showcases the expertise of UK-based organisations involved in the discovery and development of medicines, and more recently www.cambridgebiopharmacluster.co.uk – an interactive map of the Cambridge bio-pharma sector. In November 2010, Jeanette joined Liberty Property Trust and Countryside- the developers of the Cambridge Biomedical Campus – where she is
responsible for attracting companies to the Campus. She regularly hosts ABC events at the Campus aimed at bringing together Academics, Businesses and Clinicians to explore opportunities for collaboration.


 

BlankAndrew Watson
Technical Director
Object Management Group

 

 

 


 

Jim WeatherallDr Jim Weatherall

Head, Advanced Analytics Centre

AstraZeneca

Jim started life as a particle physicist, obtaining his PhD from the University of Manchester along the way.  He then spent 5 years as a scientific software consultant, developing algorithms and data-driven systems across a broad range of research sectors including petrochemicals, consumer products, laboratory automation, and pharmaceuticals.  He shifted joined AstraZeneca in 2007 as a Biomedical Informatics Scientist, went on to lead Clinical & Biomedical Informatics teams, and since 2012 has been the Head of a 30-person department called the Advanced Analytics Centre.  The AAC is focused on Clinical Data Science, whether that data be from clinical trials, or healthcare settings.  The team tackle thorny research problems in clinical drug development, using modeling & simulation, machine learning, data visualization, text mining and decision analytics.

 


 

Phil WigglesworthPhil Wigglesworth
Director
Health Analytics

Phil Wigglesworth is co-founder of Health Analytics, an award-winning provider of large-scale data processing systems to NHS customers. Phil’s background is in the software engineering and management of massive-scale internet systems. Health Analytics joins patient data from Primary, Secondary, Social, and Community Care, allowing commissioners and clinicians to manage the care actually received by patients, rather than the care delivered by their specific part of the NHS. By using modern “big data” technologies, Health Analytics transforms the NHS’s data assets into an operational tool which commissioners and clinicians use daily to improve the quality of patient care and at the same time to reduce the cost of service delivery in the NHS.

 


Mark WilsonMr Mark Wilson
Data Manager, Clinical Resource Office, University Department of Paediatrics
University of Cambridge


·         Designing and customising databases for Clinical Trial Investigative Medical Product research studies to fit particular trial requirements, incorporating data collection, data entry and quality assurance of new projects in-line with the protocol.
·         Testing and validation of new databases
·         Designing reports and providing basic statistical analyses for the purposes of monitoring progress and producing grant proposals, publications and presentations.
·         Data Collection design and transfer of data between database systems
·         Routinely updating and improving the design and functionality of study databases during study evolution.
·         Regular audit of data collection & processing plus the frequent running of quality control checks according to the requirements of GCP.
·         Development and testing of new processes and systems for the data management of Clinical Trials
·         Ensuring that databases within the Department of Paediatrics are compliant with appropriate regulatory requirements (GCP, Data Protection Act etc.)
·         Ensuring that documentation of data bases and systems is in line with GCP & ICH regulations.  Actively involved in implementing and reviewing all data-specific documentation and SOPs


 

Robert-WinterDr Robert Winter
Managing Director
Eastern Academic Health Science Network
Robert Winter has led the development of the Eastern Academic Health Science Network (EAHSN) from his role as Director of the Academic Health Science System of Cambridge University Health Partners. Formerly medical director of Cambridge University Hospitals NHS Foundation Trust from 2002-2008, Winter was National Clinical Director for the DH Respiratory Programme, 2009-2013, and is currently Vice President of the British Lung Foundation. He was appointed OBE for services to the medicine and healthcare in 2009.


 

 

John-WiseMr John Wise
Executive Director
The Pistoia Alliance (http:www.pistoiaalliance.org) is a formally incorporated, not-for-profit, cross-company, members’ organization. It is committed to lowering the barriers to innovation in life sciences R&D by improving the interoperability of R&D business processes through precompetitive collaboration.  It draws its membership widely from life science R&D including Pharma R&D, commercial information providers, technology companies and publicly-funded research institutes.  The Pistoia Alliance creates a virtual, open-innovation community by bringing together the key stakeholders to identify the root causes that lead to life science R&D inefficiencies and then develops best practices, technology implementations and standards to overcome these common obstacles.


 

BlankDr Sebastian Zeki
Postdoctoral Clinician Scientist
University of Cambridge

 

 

 

 


 

Meeting Overview with directions to venue – click here

Programme – click here

Discussion guidelines – click here

Resources and information – click here